NASDAQ: PHATPhathom Pharmaceuticals Inc Stock
$18.72-0.51 (-2.65%)
Updated Sep 19, 2024
PHAT Price
$18.72
Fair Value Price
$4.79
Market Cap
$1.12B
52 Week Low
$6.07
52 Week High
$19.71
P/E
-3.61x
P/B
-4.77x
P/S
60.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.92M
Earnings
-$297.11M
Gross Margin
80.1%
Operating Margin
-2,410.19%
Profit Margin
-2,995.7%
Debt to Equity
-2.37
Operating Cash Flow
-$215M
Beta
1.36
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PHAT Overview
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHAT ($18.72) is overvalued by 290.71% relative to our estimate of its Fair Value price of $4.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PHAT ($18.72) is not significantly undervalued (290.71%) relative to our estimate of its Fair Value price of $4.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PHAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PHAT due diligence checks available for Premium users.
Be the first to know about important PHAT news, forecast changes, insider trades & much more!
PHAT News
Valuation
PHAT fair value
Fair Value of PHAT stock based on Discounted Cash Flow (DCF)
Price
$18.72
Fair Value
$4.79
Overvalued by
290.71%
PHAT ($18.72) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PHAT ($18.72) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PHAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PHAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.61x
Industry
-135.85x
Market
25.52x
PHAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.77x
Industry
6.51x
PHAT's financial health
Profit margin
Revenue
$7.3M
Net Income
-$91.4M
Profit Margin
-1,248.6%
PHAT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PHAT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$319.4M
Liabilities
$553.2M
Debt to equity
-2.37
PHAT's short-term assets ($304.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHAT's long-term liabilities ($506.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PHAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$70.7M
Investing
-$46.0k
Financing
$24.8M
PHAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHAT vs Biotech Stocks
Phathom Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.